On the other hand, LNCaP prostate cancer cells that are inherited with both nuclear AR and ZIP-9, respond to testosterone by initiating metastatic migratory mechanism [66], and therefore testosterone lowering treatment in transgender women may be favorable in controlling metastasis if the cancer cells carry nuclear AR and ZIP-9. This evidence concerns the gene AR and prostate cancer.